Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma | Zendy

Patrick J. Stiff | Zendy; Joseph M. Unger | Zendy; James R. Cook | Zendy; Louis S. Constine | Zendy; Stephen Couban | Zendy; Douglas A. Stewart | Zendy; Thomas C. Shea | Zendy; Pierluigi Porcu | Zendy; Jane N. Winter | Zendy; Brad S. Kahl | Zendy; Thomas P. Miller | Zendy; Raymond R. Tubbs | Zendy; Deborah Marcellus | Zendy; Jonathan W. Friedberg | Zendy; Kevin Barton | Zendy; Glenn Mills | Zendy; Michael LeBlanc | Zendy; Lisa M. Rimsza | Zendy; Stephen J. Forman | Zendy; Richard I. Fisher | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma

Author(s) -

Patrick J. Stiff,

Joseph M. Unger,

James R. Cook,

Louis S. Constine,

Stephen Couban,

Douglas A. Stewart,

Thomas C. Shea,

Pierluigi Porcu,

Jane N. Winter,

Brad S. Kahl,

Thomas P. Miller,

Raymond R. Tubbs,

Deborah Marcellus,

Jonathan W. Friedberg,

Kevin Barton,

Glenn Mills,

Michael LeBlanc,

Lisa M. Rimsza,

Stephen J. Forman,

Richard I. Fisher

Publication year - 2013

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1301077

Subject(s) - medicine , hazard ratio , autologous stem cell transplantation , transplantation , rituximab , vincristine , induction chemotherapy , prednisone , surgery , international prognostic index , chop , cyclophosphamide , chemotherapy , lymphoma , oncology , gastroenterology , confidence interval

The efficacy of autologous stem-cell transplantation during the first remission in patients with diffuse, aggressive non-Hodgkin's lymphoma classified as high-intermediate risk or high risk on the International Prognostic Index remains controversial and is untested in the rituximab era.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research